Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Association of Apolipoprotein E Polymorphism with Intravitreal Ranibizumab Treatment Outcomes in Age-Related Macular Degeneration.

Bakbak B, Ozturk BT, Zamani AG, Gonul S, Iyit N, Gedik S, Yıldırım MS.

Curr Eye Res. 2016 Jun;41(6):862-6. doi: 10.3109/02713683.2015.1067325. Epub 2015 Sep 23.

PMID:
26398858
2.

Cumulative effect of risk alleles in CFH, ARMS2, and VEGFA on the response to ranibizumab treatment in age-related macular degeneration.

Smailhodzic D, Muether PS, Chen J, Kwestro A, Zhang AY, Omar A, Van de Ven JP, Keunen JE, Kirchhof B, Hoyng CB, Klevering BJ, Koenekoop RK, Fauser S, den Hollander AI.

Ophthalmology. 2012 Nov;119(11):2304-11. doi: 10.1016/j.ophtha.2012.05.040. Epub 2012 Jul 26.

PMID:
22840423
3.

Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.

Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N.

Am J Ophthalmol. 2012 Jul;154(1):125-36. doi: 10.1016/j.ajo.2012.01.010. Epub 2012 Apr 1.

PMID:
22465368
4.

Variants in the VEGFA gene and treatment outcome after anti-VEGF treatment for neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Makalic E, Schmidt DF, Sandhu SS, Baird PN, Guymer RH.

Ophthalmology. 2013 Jan;120(1):115-21. doi: 10.1016/j.ophtha.2012.10.006. Epub 2012 Nov 11.

PMID:
23149126
5.

Predictive value of VEGF A and VEGFR2 polymorphisms in the response to intravitreal ranibizumab treatment for wet AMD.

Cruz-Gonzalez F, Cabrillo-Estévez L, López-Valverde G, Cieza-Borrella C, Hernández-Galilea E, González-Sarmiento R.

Graefes Arch Clin Exp Ophthalmol. 2014 Mar;252(3):469-75. doi: 10.1007/s00417-014-2585-7. Epub 2014 Feb 13.

PMID:
24522370
6.

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.

Brown DM, Chen E, Mariani A, Major JC Jr; SAVE Study Group.

Ophthalmology. 2013 Feb;120(2):349-54. doi: 10.1016/j.ophtha.2012.08.008. Epub 2012 Nov 3.

PMID:
23131717
7.

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.

Abedi F, Wickremasinghe S, Richardson AJ, Islam AF, Guymer RH, Baird PN.

Ophthalmology. 2013 Aug;120(8):1641-8. doi: 10.1016/j.ophtha.2013.01.014. Epub 2013 Apr 9.

PMID:
23582991
8.

ARMS2 A69S polymorphism is associated with the number of ranibizumab injections needed for exudative age-related macular degeneration in a pro re nata regimen during 4 years of follow-up.

Valverde-Megías A, Veganzones-de-Castro S, Donate-López J, Maestro-de-Las-Casas ML, Megías-Fresno A, García-Feijoo J.

Graefes Arch Clin Exp Ophthalmol. 2017 Nov;255(11):2091-2098. doi: 10.1007/s00417-017-3748-0. Epub 2017 Jul 25.

PMID:
28744656
9.

Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.

Piermarocchi S, Miotto S, Colavito D, Leon A, Segato T.

Acta Ophthalmol. 2015 Sep;93(6):e451-7. doi: 10.1111/aos.12587. Epub 2014 Nov 17.

10.

Factors Associated with Recurrence of Age-Related Macular Degeneration after Anti-Vascular Endothelial Growth Factor Treatment: A Retrospective Cohort Study.

Kuroda Y, Yamashiro K, Miyake M, Yoshikawa M, Nakanishi H, Oishi A, Tamura H, Ooto S, Tsujikawa A, Yoshimura N.

Ophthalmology. 2015 Nov;122(11):2303-10. doi: 10.1016/j.ophtha.2015.06.053. Epub 2015 Aug 11.

PMID:
26271842
11.

Treatment for neovascular age-related macular degeneration in Sweden: outcomes at seven years in the Swedish Macula Register.

Westborg I, Granstam E, Rosso A, Albrecht S, Karlsson N, Lövestam-Adrian M.

Acta Ophthalmol. 2017 Dec;95(8):787-795. doi: 10.1111/aos.13539. Epub 2017 Aug 21.

12.

Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.

Jaffe GJ, Ciulla TA, Ciardella AP, Devin F, Dugel PU, Eandi CM, Masonson H, Monés J, Pearlman JA, Quaranta-El Maftouhi M, Ricci F, Westby K, Patel SC.

Ophthalmology. 2017 Feb;124(2):224-234. doi: 10.1016/j.ophtha.2016.10.010. Epub 2016 Oct 28.

PMID:
28029445
13.

Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.

Zhu M, Chew JK, Broadhead GK, Luo K, Joachim N, Hong T, Syed A, Chang AA.

Graefes Arch Clin Exp Ophthalmol. 2015 Aug;253(8):1217-25. doi: 10.1007/s00417-014-2799-8. Epub 2014 Sep 10.

PMID:
25205618
14.

Results of flexible ranibizumab treatment in age-related macular degeneration and search for parameters with impact on outcome.

Gerding H, Loukopoulos V, Riese J, Hefner L, Timmermann M.

Graefes Arch Clin Exp Ophthalmol. 2011 May;249(5):653-62. doi: 10.1007/s00417-011-1636-6. Epub 2011 Mar 9.

PMID:
21387180
15.

NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH ADVANCED VISUAL LOSS TREATED WITH ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: Clinical Outcome and Prognostic Indicators.

Vogel RN, Davis DB, Kimura BH, Rathinavelu S, Graves GS, Szabo A, Han DP.

Retina. 2017 Feb;37(2):257-264. doi: 10.1097/IAE.0000000000001150.

PMID:
27429385
16.

VEGFR2 Gene Polymorphisms and Response to Anti-Vascular Endothelial Growth Factor Therapy in Age-Related Macular Degeneration.

Hagstrom SA, Ying GS, Maguire MG, Martin DF; CATT Research Group, Gibson J, Lotery A, Chakravarthy U; IVAN Study Investigators.

Ophthalmology. 2015 Aug;122(8):1563-8. doi: 10.1016/j.ophtha.2015.04.024. Epub 2015 May 28.

17.

Intravitreal Ranibizumab in Daily Clinical Practice for Age-Related Macular Degeneration: Treatment of Exudative Age-Related Macular Degeneration in Real Life.

Cazet-Supervielle A, Gozlan J, Cabasson S, Boissonnot M, Manic H, Leveziel N.

Ophthalmologica. 2015;234(1):26-32. doi: 10.1159/000430470. Epub 2015 Jun 19.

PMID:
26111575
19.

Ranibizumab for exudative AMD in a clinical setting: differences between 2007 and 2010.

Cohen SY, Dubois L, Ayrault S, Dourmad P, Delahaye-Mazza C, Fajnkuchen F, Nghiem-Buffet S, Quentel G, Tadayoni R.

Graefes Arch Clin Exp Ophthalmol. 2013 Nov;251(11):2499-503. doi: 10.1007/s00417-013-2338-z. Epub 2013 Apr 19.

PMID:
23604514
20.

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.

Wykoff CC, Croft DE, Brown DM, Wang R, Payne JF, Clark L, Abdelfattah NS, Sadda SR; TREX-AMD Study Group.

Ophthalmology. 2015 Dec;122(12):2514-22. doi: 10.1016/j.ophtha.2015.08.009. Epub 2015 Sep 29.

Supplemental Content

Support Center